Cas:86912-84-7 1-(3-chlorophenoxy)but-3-yn-2-ol manufacturer & supplier

Chemical Name:1-(3-chlorophenoxy)but-3-yn-2-ol

CAS.NO:86912-84-7

Synonyms:1-(3-CHLOROPHENOXY)-3-BUTYN-2-OL;(+/-)-4-(3-chlorophenoxy)-1-butyne-3-ol;MFCD09909563

Molecular Formula:C₁₀H₉ClO₂

Molecular Weight:196.63000

HS Code:2909499000

Physical and Chemical Properties:

Melting point:36-40ºC

Boiling point:327.1ºC at 760 mmHg

Density:1.255g/cm3

Index of Refraction:1.565

PSA:29.46000

Exact Mass:196.02900

LogP:1.71290

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(3-CHLOROPHENOXY)-3-BUTYN-2-OL chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD09909563 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(3-CHLOROPHENOXY)-3-BUTYN-2-OL Use and application,(+/-)-4-(3-chlorophenoxy)-1-butyne-3-ol technical grade,usp/ep/jp grade.

Related News: The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. 1-(3-chlorophenoxy)but-3-yn-2-ol manufacturer However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. 1-(3-chlorophenoxy)but-3-yn-2-ol supplier Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress. 1-(3-chlorophenoxy)but-3-yn-2-ol vendor Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 1-(3-chlorophenoxy)but-3-yn-2-ol factory Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.